Connect with us

Media OutReach

Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland

Published

on

HONG KONG SAR – Media OutReach Newswire – 1 August 2025 – Cushman & Wakefield, a leading global real estate services firm, today released its Life Sciences on the Chinese Mainland Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland report. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector.

Policy Landscape National and Local Catalysts

Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development.

Recent national policy initiatives on the Chinese mainland

Types of policies Detail information
Opening to Foreign Investment In 2024, China eased restrictions on foreign investments in stem cell research, gene therapy, and genetic diagnostics within Free Trade Zones (FTZs) like Beijing, Shanghai, Guangdong, and Hainan.
Regulatory Incentives The State Council’s Circular No. 53 introduced measures such as regulatory data protection and marketing exclusivity for select pharmaceutical products, including orphan and paediatric drugs.
Wholly Foreign-Owned Hospitals China now permits the establishment of wholly foreign-owned hospitals in cities like Beijing, Shanghai, and Shenzhen, enhancing healthcare services and encouraging foreign investment.

Source: Cushman & Wakefield Research

Industry Innovation and Company Growth

Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland’s global relevance in life sciences.

Real Estate Development and Regional Hubs

Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors.

The R&D + Manufacturing + Service” ecosystem
Source: Cushman & Wakefield Research

Landlord Perspectives Evolving Real Estate Models

Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments.

Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners.

Occupier Perspectives Growth, Innovation, and Challenges

Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility.

In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market.

Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, “Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value.”

Johnathan Wei, President, Project & Occupier Services, China, said, “Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation”.

Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said,” Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals”.

Shaun Brodie, Head of Research Content, Greater China, “Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value”.

Please click here to download the full report.

Hashtag: #Cushman&Wakefield

The issuer is solely responsible for the content of this announcement.

About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2024, the firm reported revenue of $9.4 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit or follow us on LinkedIn ().

Advertisement

Media OutReach

New Documentary A MONA LISA OBSESSION from Discovery to debut December 14 in Southeast Asia

Published

on

SINGAPORE – Media OutReach Newswire – 10 December 2025 – A brand-new documentary A Mona Lisa Obsession explores various perspectives of the Mona Lisa, an iconic masterpiece by Leonardo da Vinci, set to air in Southeast Asia on the Discovery Channel on Thursday, December 11 2025 at 7:10 PM and on Discovery Asia on Sunday, December 14 at 9:00 PM.

A Mona Lisa Obsession touches on the origins of the Mona Lisa, from the Italian Renaissance, and the painting’s passage through France with King Francis l and Napoleon Bonaparte, to the Louvre – the documentary also zooms in on a rare private art collection in Taiwan which includes a likeness of the painting of Mona Lisa, a work of art that some consider to be a youthful depiction reminiscent of Mona Lisa.

Owned by Frank Huang, an art collector and Taiwanese technology leader from Taiwan, this depiction of the Mona Lisa from his private collection adds a unique perspective to the ongoing conversation surrounding one of Leonardo da Vinci’s most iconic works.

The Mona Lisa has long captivated the world with her enigmatic smile and mysterious gaze – over centuries, many artistic interpretations inspired by the Mona Lisa have emerged, with scholars discovering more hidden details and subtle symbols, fueling the fascination of the original painting.

Catch A Mona Lisa Obsession in Southeast Asia on the Discovery Channel, Thursday, December 11, 2025 at 7:10 PM SGT and on Discovery Asia on Sunday, December 14 at 9:00 PM SGT.

****

Note to editors:

  • Watch highlights here
  • Download stills here

The issuer is solely responsible for the content of this announcement.

About Discovery Channel

Across every platform, Discovery Channel is dedicated to connecting audiences who have a passion for adventure and crave a connection to the world around them. Popular series including Deadliest Catch, Expedition Unknown and Gold Rush, along with Shark Week, the annual tentpole programming event, serve as trusted portals that transport viewers directly into thrilling, real, high stakes moments. Through smart, authentic characters whose stories inform and inspire, Discovery celebrates the men and women who will stop at nothing to explore new spaces and achieve their dreams. For more information, please visit

Continue Reading

Media OutReach

Financial Stress Keeps Singapore Awake, while Overall Well-Being in APAC Lags Behind Global Peers

Published

on

Promotion of exercise culture and therapy may boost physical and mental health

SINGAPORE – Media OutReach Newswire – 10 December 2025 – Despite mounting stress due to sustained concerns with the cost of living, vitality and overall well-being levels in Singapore remain consistent with last year. However, stress has a demonstrable effect on respondents’ mental and physical well-being, signaling the importance of a holistic approach to healthcare that encompasses both aspects.

The Singapore report of the Cigna Healthcare International Health Study 2025, released today encompasses more than 11,000 respondents across 13 markets, including 1,000 in Singapore and 4,000 across the Asia-Pacific region. The study reveals that physical, mental and financial well-being are the three aspects prioritized by Singapore residents. However, financial well-being is ranked the lowest with almost four in 10 (39%) rating their financial health as “fair” or “poor”.

Raymond Ng, CEO & Country Manager, Cigna Healthcare Singapore & Australia said: “Health and vitality are key to building resilient communities. It promises the well-being of our workforce and enables us to grow and prosper as a society. While vitality and well-being levels held firm among Singapore residents, more needs to be done in today’s uncertain environment to tackle stressors that can negatively impact their physical and mental well-being.”

The key indicators of vitality and well-being in Singapore are as follows:

Vitality Score Overall Well-Being

(% rating as “excellent” or “very good”)

Top Three Areas of Well-Being

(% rating as “excellent” or “very good” in 2025)

2025: 61.2

2024: 61.4

2025: 34%

2024: 33%

Family well-being: 44%

Mental well-being: 36%

Physical well-being: 34%


On a regional level, overall well-being in Asia Pacific lags behind the global average, with less than three in 10 (28%) Asia-Pacific respondents rating their overall well-being as “excellent” or “very good”, compared to four in 10 (41%) globally. While physical and mental well-being are the two most important aspects of well-being for respondents globally, financial well-being is more important for those in Asia Pacific, coming in as the third most important aspect. With financial well-being remaining the weakest aspect across the globe, there is a pressing need for governments and organizations to render support to address financial concerns.

Robert Peat, Chief Executive Officer, Asia Pacific, Cigna Healthcare said: “Asia Pacific continues to be one of the fastest growing regions in the world. To sustain this momentum, communities and employers need to recognize that healthy people are the foundation of a healthy economy and implement measures to close the gaps in their well-being.”

Sleepless in Singapore: Financial stress as the sleep killer

While mental well-being in Singapore remains stable with more than a third of respondents rating it as “excellent” or “very good” this year, eight in 10 (79%) respondents are stressed. Their greatest stressors are the current cost of living (53%); uncertainty about the future (47%); and personal finance (43%).

Stress affects more than mental and emotional health and can have huge implications on physical well-being. Our study reveals that disrupted sleep is the most common effect of stress among respondents in the nation, with close to half (48%) of respondents who are stressed reporting this effect, compared to 38% regionally.

Therapy remains underused by Singapore respondents. Despite nearly half (49%) of respondents reporting being negatively impacted by poor mental health, nearly nine in 10 (89%) say they did not receive counselling or therapy in the past 12 months, with 77% believing they do not need it. Given the impacts of stress and poor mental health on physical and overall well-being, more efforts are needed to raise awareness about the benefits of therapy and destigmatize seeking help.

Exercise culture runs strong in Singapore

More than a quarter (26%) of respondents in Singapore rate their exercise habits as “excellent” or “very good”.

When asked how they manage their weight, two-thirds (66%) said they exercise regularly, higher than the Asia-Pacific average of 61%; with only 4% of Singapore respondents turning to medication for weight management. The findings underscore a relatively strong exercise culture and the prioritization of healthy habits among those living in the nation. Communities and organizations may leverage the growing fitness trend to enhance physical well-being.

Cautious optimism around AI in healthcare

Close to half (47%) of Singapore respondents are positive about the impact of AI on healthcare, with 45% expecting it will reduce wait times within three years. This could have an outsized impact in Singapore, as respondents here are 29% more likely to have delayed or avoided getting care due to concern with wait times than their regional counterparts.

Additionally, almost half of Singapore respondents (48%) mention a reduction in human interaction as an expected change with the advent of AI. The challenge ahead is striking the right balance between efficiency and empathy.

The full findings of the report are available here.
Hashtag: #CignaHealthcare #CignaHealthcareInternationalHealthStudy #Health #Wellness #Wellbeing




The issuer is solely responsible for the content of this announcement.

Cigna Healthcare Singapore

Cigna Healthcare is a division of The Cigna Group, a global health company committed to creating a better future built on the health and vitality of every individual and every community. Cigna Healthcare is a health benefits provider that advocates for better health through every stage of life. We guide our customers through the healthcare system, empowering them with the information and insight they need to make the best choices for improving their health and vitality.

Cigna Healthcare Singapore is a strong believer of total health and wellness and prides itself on delivering personalized solutions for the health of our clients and customers. To achieve this, Cigna Healthcare Singapore works as one global team and in close partnership with its customers, network providers and communities to understand and address their diverse needs. Learn more at

Continue Reading

Media OutReach

SWISS REJU wins “JESSICA Best AI Body Slimming Award” with INDIBA

Published

on

HONG KONG SAR – Media OutReach Newswire – 10 December 2025 – SWISS REJU has earned “Best AI Slimming Treatment Award” at the prestigious JESSICA Beauty and Wellness Awards, honouring exceptional mastery of artificial intelligence in the beauty industry. SWISS REJU also announces the official launch of INDIBA, an FDA and CE approved technology that helps to burn visceral fat and contour the body, creating an even stronger technical offering for its signature, multi-award winning program “SWISS REJU K-Lipolysis”.

SWISS REJU won the “Best AI Slimming Treatment Award” at the prestigious JESSICA Beauty and Wellness Awards

The JESSICA Beauty and Wellness Awards celebrate excellence across luxury beauty, healthcare and wellness. It is one of the most recognized beauty industry awards in Hong Kong. The organizer, JESSICA, is a major lifestyle and media company. For over 25 years, JESSICA has been reporting on fashion, lifestyle and business, as one of the most trustworthy and influential media sources in Hong Kong.

“We’re incredibly fortunate to win this new, Best AI Slimming Award with JESSICA,” said the spokesperson for SWISS REJU. “Our goal was to provide our guests with top medical aesthetic technologies. Platforms like BTL EXION and INDIBA, are exactly the type of top medical technologies which SWISS REJU is heavily investing in. The breathtaking results powered by AI, reflect the endless possibilities new technologies can bring to the beauty and slimming field”

The JESSICA Beauty and Wellness Awards is extremely selective and has a rigorous nominations and editorial selection process. Only brands that have been proven to provide genuine service and excellent results are eligible to compete. Amongst the Winners this year, are Australian organic brand “CANVAS” and Japanese household name “Panasonic VITALIFT” beauty appliances.

SWISS REJU, with its heavy investment in new and prestigious technologies such as INDIBA (recently approved in Europe under the Medical Device Regulation), offers a seamless blend of traditional wellness and innovation, allowing guests to experience what many considered to be one of the most effective slimming treatments in Hong Kong. INDIBA with its trademark Proionic 448khz technology, is loved by the Top 1% most influential users in the world, amongst them European royalties, celebrity footballers and international singers.

The recognition of this major annual Award, reaffirms SWISS REJU’s commitment to exceptional technology. It is the 12th annual award won by the brand, representing a new record.

SWISS REJU and integrative power of cutting edge technologies

SWISS REJU’s trademarked “K-Lipolysis” body contouring program offers winning technologies including INDIBA, BTL EXION, Winback, ATP LIPO X, amongst others. It is the unique contouring solution beauty lovers are craving for.
Hashtag: #SWISSREJU #熱光溶脂

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending